Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STK-012 alone and with standard therapy in first-line advanced non-squamous NSCLC
2025-522632-14-00Phase 2Authorised
- Sponsor
- Synthekine
- Start
- May 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial of stk-012 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Synthekine. Primary endpoint: Objective response rate. Planned start May 2026; status: authorised.
02
Drugs
stk-012
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522632-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522632-14-00.